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Abstract 
Background: Even though bleeding and thromboembolic events are major complications of extracorporeal 
membrane oxygenation (ECMO), data on the incidence of venous thrombosis (VT) and thromboembolism (VTE) 
under ECMO are scarce. This study analyzes the incidence and predictors of VTE in patients treated with ECMO due to 
respiratory failure.
Methods: Retrospective analysis of patients treated on ECMO in our center from 04/2010 to 11/2015. Patients with 
thromboembolic events prior to admission were excluded. Diagnosis was made by imaging in survivors and postmor-
tem examination in deceased patients.
Results: Out of 102 screened cases, 42 survivors and 21 autopsy cases [mean age 46.0 ± 14.4 years; 37 (58.7 %) 
males] fulfilling the above-mentioned criteria were included. Thirty-four patients (54.0 %) underwent ECMO therapy 
due to ARDS, and 29 patients (46.0 %) with chronic organ failure were bridged to lung transplantation. Despite 
systemic anticoagulation at a mean PTT of 50.6 ± 12.8 s, [VT/VTE 47.0 ± 12.3 s and no VT/VTE 53.63 ± 12.51 s 
(p = 0.037)], VT and/or VTE was observed in 29 cases (46.1 %). The rate of V. cava thrombosis was 15/29 (51.7 %). Diag-
nosis of pulmonary embolism prevailed in deceased patients [5/21 (23.8 %) vs. 2/42 (4.8 %) (p = 0.036)]. In a multivari-
able analysis, only aPTT and time on ECMO predicted VT/VTE. There was no difference in the incidence of clinically 
diagnosed VT in ECMO survivors and autopsy findings.
Conclusions: Venous thrombosis and thromboembolism following ECMO therapy are frequent. Quality of antico-
agulation and ECMO runtime predicted thromboembolic events.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
In 1855, Rudolf Virchow established a theory on coagula-
tion [1]. His triad of causes for thrombogenesis consist-
ing of increased blood viscosity, altered blood flow and 
endothelial injury is still valid [2]. When transferring 
Virchow’s triad to patients on extracorporeal membrane 
oxygenation (ECMO), they are at high risk of thrombosis 
and thromboembolism. Pump-induced platelet activa-
tion as well as inflammation and consumption of clot-
ting factors due to mechanic stress and blood contact to 
foreign surfaces provokes hypercoagulability [3, 4]. Can-
nulation induces endothelial injury and ECMO induces 
blood flow disturbances, resulting in regional stasis to 
complete the risk profile. The increasing use of ECMO 
drives a progressive improvement of pumps and circuits, 
e.g., centrifugal pumps and heparin coating, reducing 
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the incidence of thrombosis inside the device, seemingly 
allowing a reduction of anticoagulation [4].
Although bleeding and thromboembolic complications 
are feared complications during ECMO therapy and both 
contribute to mortality [5], the risk of venous thrombo-
sis (VT) and thromboembolism (VTE) has just recently 
started gaining attention. Case reports and case series 
indicate that VT and VTE might influence outcome as 
well [6–10]. VTE were concurrently diagnosed in up to 
10 % of cases [11] and in up to 18 % with routinely per-
formed postdecannulation venous Doppler ultrasound 
[12]. Autopsy results of patients on veno-arterial ECMO 
support after cardiac surgery showed VT in 32 % of cases 
with a duration-dependent increase [13]. Considering the 
longstanding support of respiratory ECMO especially 
in patients that are bridged to lung transplantation [14], 
the true incidence of VT is probably still underestimated. 
This study aimed to evaluate the incidence of clinically 
diagnosed venous thrombosis and thromboembolism in 
patients treated with ECMO due to respiratory failure.
Methods
Study subjects
From a computerized database, we retrieved all patients 
who underwent high-flow ECMO at the pulmonary ICU 
at the University Hospital of Saarland (1.300 bed tertiary 
care hospital) from 04/2010 to 11/2015. This retrospec-
tive analysis includes all patients who survived ECMO 
therapy and could be discharged from ICU and autopsy 
findings of deceased patients treated in the same era. 
Patients that did not survive to discharge and for whom 
autopsy was refused are not analyzed.
Patients with preexisting thromboembolic disease 
such as acute pulmonary embolism or chronic throm-
boembolic pulmonary hypertension (CTEPH) and sub-
jects with partial autopsy (e.g., selective autopsy of the 
thorax) were excluded from this analysis. Patients on 
pump-driven ECCO2R on 1/4-inch tubing were only 
included if the system was switched to high-flow ECMO 
on 3/8-inch. Four cases with a mean ECCO2R runtime 
of 10.7 ±  10.3 days were finally changed to full ECMO. 
The analysis was approved by the institutional review 
board (IRB; Ärztekammer des Saarlandes: #194/14 and 
#115/15). The necessity for informed consent was waived 
by the IRB due to the retrospective nature of the study.
Extracorporeal membrane oxygenation/ECMO 
deployment/continuous veno‑venous hemodiafiltration 
(CVVHD)
ECMO was initiated if PaO2/FiO2 (mmHg) was below 
100 or if pH was below 7.20 for respiratory causes despite 
optimal conventional treatment. Patients had to have 
a potentially reversible cause of respiratory failure or 
the perspective of lung transplantation. Awake ECMO 
was initiated to prevent intubation in patients that 
were hypoxemic and/or hypercapnic (pH was below 
7.20 or PaO2/FiO2 (mmHg) below 100) despite high 
FiO2. Twenty-nine patients had ECMO as a bridge to 
transplantation.
All patients were treated with veno-venous (vv) ECMO 
using mostly the femoral (draining) and jugular (return) 
veins as cannula entry sites. As a standard, we used 23 F 
draining cannulae at a length of 38 or 55 cm, as appro-
priate, and 19 F returning cannulae (Maquet, Rastatt, 
Germany) with a heparin coating. Eleven patients were 
cannulated with a bicaval double-lumen cannula (27 
F or 31 F Avalon Elite, Avalon Laboratories, Rancho 
Dominguez, USA). Cannulation was done ultrasound-
guided percutaneously by the staff intensivists. As stand-
ard oxygenator, a 7.0L-HLS or Quadrox-I primed with 
physiological saline solution on the Maquet CardioHelp 
platform was used. All tubings were 3/8 inch. ECMO cir-
cuits and oxygenators were visually checked for clots on 
a daily basis. Sedation was administered according to a 
protocol. Daily interruption of sedation was mandatory, 
except in hemodynamically unstable patients. The hemo-
dynamic situation was monitored using an arterial and 
central venous line and pulmonary artery catheter when 
appropriate. Patients were weaned off vasopressors and 
sedation, whenever possible. Patients previously intu-
bated and mechanically ventilated underwent tracheos-
tomy, if extubation and awake ECMO were not possible.
CVVHD was done in all patients with regional cit-
rate anticoagulation (Multifiltrate CiCa, Fresenius, Bad 
Homburg, Germany). The concentration of ionized cal-
cium in the extracorporeal circuit is reduced to 0.25–
0.35  mmol/L through chelation with citrate. Calcium is 
effectively eliminated during dialysis. To restore a physi-
ological calcium level (normal range 2.2–2.6  mmol/L), 
calcium was added prior to return of the dialyzed blood 
to the patient’s circulation.
Anticoagulation and transfusion
All patients were primarily treated with unfractionated 
heparin; in case of suspected heparin-induced thrombo-
cytopenia (HIT), the regimen was switched to argatroban 
and HIT testing was performed. Patients that were HIT 
negative were switched back to heparin. The Extracor-
poreal Life Support Organization’s (ELSO) guidelines 
for anticoagulation were considered for anticoagulation 
management (http://www.elso.org/Resources/Guide-
lines.aspx). Additionally, we guided heparinization 
according to ECMO flow and aimed at >50 s for activated 
partial thrombin time at an ECMO flow ≥4.0 L/min. We 
aimed at higher aPTTs if ECMO flow was lower. We cal-
culated the percentage of PTT above 50 s (number PTT 
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values over 50  s divided by the total number of aPTT 
measurements times 100) to assess the effectiveness of 
anticoagulation and proportion of patients that were 
within the target range. In comparison with mean values 
of aPTT, this approach gives a more meaningful state-
ment with regard to the quality of anticoagulation over a 
longer period of time.
Transfusion trigger for packed red blood cells (PRBC) 
according to our institutional protocol was central 
venous oxygen saturation (ScvO2) ≤65  % (despite opti-
mal inotropic support if needed) and/or Hb ≤ 7.0 g/dL. 
Platelets were substituted if platelet count was below 20/
µL or if diffuse bleeding occurred. Fresh frozen plasma 
(FFP) was substituted to optimize plasmatic coagulation 
and occasionally in  situations of disseminated intravas-
cular coagulation (DIC). Fibrinogen, PPSB (prothrom-
bin-complex), factor XIII and ATIII were used as well 
according to the situation.
Postmortem examination
We aimed for postmortem examination for all patients 
who died in our department. The autopsy was finally per-
formed if the deceased or his relatives had agreed. The 
examination was performed following a standard proto-
col. Subjects receiving partial autopsy only were excluded 
from the analysis.
Laboratory values
Routine laboratory values were determined directly prior 
to ECMO initiation and on a daily basis until cessation. 
Coagulation parameters including factors were deter-
mined only if bleeding was considered a problem. In 
cases of external cannulation and patient admission from 
external hospitals, laboratory values for the first days on 
ECMO were missing.
Diagnosis of VT/VTE
Follow-up was done by analyzing all patients’ charts, 
available imaging data and autopsy results up to 1  year 
after ECMO therapy. Diagnosis was based on duplex 
sonography, CT scan or magnetic resonance angiogra-
phy (MRA). In one case of clinically suspected pulmo-
nary embolism after cannula removal, diagnosis without 
imaging was accepted. Screening data were complete for 
81 % of patients.
Statistical analysis
We described categorical data using frequencies and per-
centages. For continuous data, we used means and stand-
ard deviations as well as Kolmogorov–Smirnov test to 
check for normal distribution.
In bivariable analyses, we used Fisher’s exact test for 
categorical variables and Mann–Whitney U test or 
Student’s t test for continuous variables as appropri-
ate. Variables with a p value of less than 0.1 in bivariable 
analyses were considered for a multivariable binary logis-
tic regression model in order to estimate odds ratios and 
95 % confidence intervals.
All statistical tests were two-sided, and p values of less 
than 0.5 were considered statistically significant. Statisti-
cal analyses were performed using IBM SPSS Statistics 
version 21 (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
In total, data from 102 patients who underwent high-flow 
ECMO support were screened. Ninety-six patients were 
treated on the pulmonary ICU. Additionally, six patients 
treated on other ICUs on campus fulfilling the above-
mentioned criteria and undergoing postmortem analysis 
were included. 44/96 patients (45.8  %) could be weaned 
from the device and discharged from ICU. 52/96 patients 
(54.1  %) died during extracorporeal support or within 
their ICU stay. Autopsy was refused in 29/52 cases (56 %).
We excluded all patients with preexisting VT/VTE and 
subjects with partial autopsy from the analysis. Two sur-
viving patients, one had chronic thromboembolic pulmo-
nary hypertension (CTEPH) and the other a thrombus in 
the right atrium on admission, as well as 8 autopsy cases 
were excluded.
Consequently, 63 patients treated from May 2010 to 
November 2015 were included in this retrospective anal-
ysis. Figure 1 shows the consort diagram for all subjects. 
The majority of patients were male [37/63 (59 %)], mean 
age was 46.0 ± 14.4 years, and mean time of ECMO sup-
port was 22.4 ±  17.0  days. Mean body mass index was 
28.3 ± 9.8 kg/m2.
The main reason for ECMO initiation was bridge to 
recovery in acute respiratory distress syndrome (ARDS) 
in 34/63 patients (54 %). All, except one patient with car-
diogenic shock, had pulmonary ARDS. The other patients 
(29/63; 46  %) had chronic or acute on chronic respira-
tory failure. In these patients, ECMO was initiated as a 
bridging procedure to lung transplantation. Underlying 
diseases were interstitial lung disease (14/29), cystic fibro-
sis (10/29), COPD (4/29) and pulmonary hypertension 
(1/29). In cases of external cannulation and patient admis-
sion from external hospitals, laboratory values for the first 
days on ECMO were frequently missing; this occurred in 
four patients concerning 5.6 ± 4.7 ECMO-days.
11 of 63 (17.5 %) patients were cannulated with a bicaval 
double-lumen cannula. Causes of death in the 21 patients 
undergoing postmortem examination were septic-toxic 
multiorgan failure in 17 (80.9  %) patients, two patients 
had acute right heart failure due to pulmonary embolism 
(9.5 %), one patient (4.8 %) died from cerebral edema and 
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one patient (4.8 %) died from cerebral hemorrhage. Base-
line characteristics are summarized in Table 1.
VT/VTE incidence
Documented evaluation after clinical suspicion regarding 
VT/VTE was done in 51/63 patients (81.0 %), resulting in 
VT and VTE diagnosis in 29/63 (46.1 %) patients. In 24 of 
these 29 (83 %) patients, thrombosis was rated as cannula 
associated. Main thrombus localization was the inferior 
vena cava (IVC) in 15/29 (51.7 %) and internal jugular vein 
(IJV) in 14/29 cases (48.2 %). 8/29 patients (27.6 %) pre-
sented with thrombosis in more than one vein (Table 2).
Pulmonary embolism (PE) was diagnosed in 7/63 
patients (11.1  %). PE was significantly more frequent in 
deceased patients than in survivors (p = 0.036). However, 
incidence of VT did not differ between these groups.
Time on ECMO
Time on ECMO was statistically significant longer in 
patients diagnosed with VT/VTE than in patients with-
out (p  =  0.040). Mean ECMO time in patients with a 
thromboembolic event was 27.7 ±  19.7 days, compared 
to 17.9 ± 13.9 days in those patients without.
Laboratory parameters, transfusion and substitution 
of coagulation factors
Analyzing mean laboratory values during ECMO ther-
apy, we observed a significantly lower PTT (47.0 ± 12.3 
vs. 53.6 ± 12.5 s; p = 0.037) in patients with diagnosed 
VT/VTE. The percentage of PTT values over 50  s was 
significantly reduced in patients with VT/VTE (31 ± 27 
vs. 48 ± 27 %; p = 0.015).
In addition, VT/VTE patients had signifi-
cantly lower fibrinogen levels (315.16  ±  77.97 vs. 
406.60  ±  164.18  mg/dL; p  =  0.026). Highly ele-
vated D-dimers were seen in both groups of patients 
(p  =  0.169). CRP-values were not different between 
groups (p  =  0.679). Laboratory results are shown in 
Table  3. Platelet levels were not different between 
groups (p =  0.092). Mean hemoglobin levels were not 
different between groups; however, patients with VT/
VTE received more transfusions of RPBC over time to 
achieve the same levels of hemoglobin, but the differ-
ences did not reach statistical significance (p = 0.068).
Transfusion of blood products and derivates are sum-
marized in Table 4. PRBC and FFP were included in the 
multivariable analysis.
When we compared different factors between 
the groups VT/VTE and no VT/VTE, time on 
ECMO,  %aPTT > 50 s, fibrinogen, amount of fresh fro-
zen plasma (FFP) and packed red blood cells (PRBC) 
transfused yielded p values of less than 0.1 and hence 
were included in multivariable analyses. In a multivari-
able logistic regression analysis, time on ECMO and 
percentage of aPTT  >  50  s were predictors of VT/VTE 
(Table 5).
Fig. 1 Consort diagram of patients included in the analysis. Six patients from the ICUs of the Depts. of Anaesthesiology and Cardiology were added 
to the cohort that met the inclusion criteria. CTEPH chronic thromboembolic pulmonary hypertension, PA partial autopsy only, AT preexisting atrial 
thrombus
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Discussion
We set out to investigate the incidence and predictors 
of thrombosis and thromboembolism following ECMO 
therapy. Sixty-three patients, treated on ECMO in our 
center, were included in this analysis. The main findings 
of this retrospective analysis are: (1) at a rate of 46.1 %, 
thrombotic and thromboembolic events are frequent, 
(2) time on ECMO and level of anticoagulation influence 
the incidence of thrombotic and thromboembolic events 
and (3) these events tend to influence the outcome of 
these patients. Patient with a bicaval double-lumen can-
nula had no higher incidence of VT/VTE than other 
patients.
Critically ill patients are per se vulnerable for throm-
botic and thromboembolic events. Kaplan et al. [15] pub-
lished a VTE incidence of 37.2 % in ICU patients during 
severe sepsis and septic shock. Patients with viral ARDS 
are also at risk as suggested by data derived from the pan-
demic H1N1 [16]. Regarding non-infectious etiologies, 
pulmonary fibrosis is, for example, associated with a sig-
nificantly elevated risk of thromboembolic disease [17].
Over and above these baseline risks, there are some 
certain characteristics for patients treated on ECMO. 
During extracorporeal assist, modification of blood com-
position as well as foreign surface and pump-mediated 
coagulopathy is one part of the problem. Cannulation is 
another. Starting with vascular injury at cannula entry 
site, the cannula splints the vessel until central areas are 
reached. This generates long areas of low flow and stasis 
along the cannula and thus provides an ideal location for 
thrombus formation. Possibly, additional indwelling cath-
eters further obstruct the vessel. Taken together, these 
ICU patients are at high risk of VT/VTE.
However, there are still few data concerning the inci-
dence of VT following ECMO and the aspect of VTE 
following respiratory ECMO therapy has not been inves-
tigated so far.
Cooper et  al. [12] recently reported a retrospective 
analysis concerning the incidence of DVT in survivors 
of respiratory ECMO diagnosed by postdecannulation 
venous Doppler ultrasound. They used a 25 F multistage 
access cannula and a 23 F single-stage return cannula 
(Biomedicus, Mineapolis, MN) as standard cannulation 
configuration and a systemic anticoagulation with hepa-
rin aiming at a PTT of 1.5–2-times normal values. Sur-
prisingly, DVT was found in merely 13/72 (18  %) of 
cases. This low incidence might be explained by a lack 
of reporting regarding V. cava thrombosis. Additionally, 
with a reported survival rate of 79 %, this cohort might be 
different from other cohorts.
We observed VT/VTE in 30/63 patients (47.6  %) that 
were mainly femoral/jugular cannulated. Due to the fact 
Table 1 Baseline patient characteristics of study patients
CVVHD continuous veno-venous hemodialysis, VJI/VF V. jugularis interna/V. 
femoralis, BCDL bicaval double-lumen, ARDS acute respiratory distress 
syndrome, LTX lung transplantation, ILD interstitial lung disease, COPD chronic 
obstructive pulmonary disease, PH pulmonary hypertension, CF cystic fibrosis. 
Fisher’s exact test was used to examine differences between categorical 
variables, and numeric differences were analyzed using t test (Height) or 
Mann–Whitney U test as appropriate. Differences were considered as statistically 










Survivors 42 (66.7) 24 (70.6) 18 (62.1) 0.594
Male (%) 37 (58.7) 22 (59.5) 15 (40.5) 0.318
Age (years) 46.0 ± 14.4 47.6 ± 13.7 44.2 ± 15.3 0.465
Height (cm) 169.9 ± 9.7 168.8 ± 7.9 171.1 ± 11.6 0.451
Weight 70.9 ± 25.6 69.9 ± 25.2 72.1 ± 26.4 0.778
BMI 28.3 ± 9.8 27.7 ± 9.5 28.0 ± 10.3 0.390
CVVHD (%) 33 (52.4) 16 (47.1) 17 (58.6) 0.450
Time on ECMO (days) 22.4 ± 17.4 17.9 ± 13.9 27.7 ± 19.7 0.040
Cannulation
VJI/VF 52 (82.5) 27 (79.4) 25 (86.2) 0.526
BCDL cannula 11 (17.5) 7 (20.6) 4 (13.8)
Underlying disease
ARDS (%) 34 (54.0) 19 (55.8) 15 (51.7)
Pulmonary (%) 33 (97.0) 18 (52.9) 15 (51.7)
Extrapulmonary (%) 1 (3) 1 (2.9) 0 (0)
Bridge to LTX (%) 29 (46.0) 15 (44.1) 14 (48.3)
CF (%) 10 (15.9) 6 (17.6) 4 (13.8)
COPD (%) 4 (6.3) 2 (5.8) 2 (6.9)
ILD (%) 14 (22.2) 7 (20.6) 7 (24.1)
PH (%) 1 (1.6) 1 (2.9) 0 (0)
Table 2 VT/VTE imaging modalities and  thrombus locali-
zation
VT/VTE venous thrombosis/venous thromboembolism, CT computed 
tomography, MRI magnetic resonance imaging
N (%)
VT/VTE screening 51/63 (81.0)
VT diagnosis 29/63 (46.1)
Autopsy 11/29 (37.9)





Thrombosis at cannula entry side 24/29 (82.8)
V. cava 15/29 (51.7)
V. jugularis interna 14/29 (48.2)
Pulmonary embolism 7/29 (24.3)
Multiple thrombosis sites 8/29 (27.6)
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that thrombosis was mainly cannula associated, the IJV 
(46.7 %) and the IVC (50 %) were the most affected veins. 
A recent publication by Shafi et  al. [8] reported upper-
extremity deep vein thrombosis in 80 % of cases in a case 
series of 10 patients who were put on vvECMO with a 
dual-lumen cannula. In our present analysis, the rate of 
thrombosis associated with dual-lumen cannulas was not 
significantly different from other cannulation types and 
occurred in 4/11 cases (36.4 %).
To the best of our knowledge, this analysis is the first 
showing a high incidence of IVC thrombosis in ECMO 
patients. IVC thrombosis might account for roughly 2 % 
of lower limb deep vein thrombosis (DVT) [18]. IVC 
thrombosis harbors a 12–30 % risk of PE and a relevant 
risk of long-term complications such as chronic venous 
insufficiency, venous congestion and postthrombotic 
syndrome in up to 20 % of non-resolved thrombosis [18, 
19]. PE as a major complication of VT was consequently 
diagnosed in 7/63 cases (11 %). We found one case of sus-
pected PE directly following cannula removal and two 
cases of incidental PE diagnosed by CT scan. In most 
cases, VTs at cannulation sites are adherent to the venous 
wall and do not cause clinical symptoms. Up to now, 
there is no relevant literature on long-term complications 
following cannula-associated VT.
Table 3 Laboratory measurements in ECMO patients
aPTT activated partial thromboplastin time, INR international normalized ratio, %aPTT denotes the number PTT values over 50 s divided by the total number of aPTT 
measurements times 100 (e.g., in the No VT/VTE group, patients had 48.35 % of measured values >50 s). Values are mean ± SD. Differences were analyzed using t test 
or Mann–Whitney U test (used for platelet count, aPTT, INR, fibrinogen, Factor X, XII, hemoglobin and CRP). Differences were considered as statistically significant if 
p ≤ 0.05
N Ref. All (N = 63) No VT/VTE (N = 34) VT/VTE (N = 29) p
Hemoglobin (g/dl) 63 12–18 9.24 ± 0.73 9.25 ± 0.77 9.23 ± 0.96 0.994
Platelet count (platelets/µl) 63 140–400 143.09 ± 70.67 155.21 ± 85.50 128.88 ± 45.35 0.160
aPTT (s) 63 21–34 50.60 ± 12.75 53.63 ± 12.51 47.07 ± 12.30 0.037
%aPTT (s) > 50 s 63 n.a. 40.4 ± 28.5 % 48.35 ± 27.23 % 30.99 ± 27.41 % 0.015
INR 63 0.85–1.15 1.31 ± 0.50 1.30 ± 0.58 1.32 ± 0.39 0.148
Fibrinogen (mg/dl) 63 180–400 364.71 ± 138.5 406.60 ± 164.18 315.16 ± 77.97 0.026
C-reactive protein (mg/l) 63 0–5 120.77 ± 68.93 122.52 ± 78.85 118.73 ± 56.44 0.679
D-dimers (mg/l) 45 < 5 14.48 ± 7.79 12.68 ± 7.35 15.92 ± 7.98 0.169
Factor II (%) 35 70–120 84.57 ± 27.58 90.05 ± 25.66 80.45 ± 28.89 0.316
Factor V (%) 37 70–120 97.99 ± 25.44 104.48 ± 27.65 93.48 ± 22.64 0.155
Factor VII (%) 37 50–200 80.47 ± 22.36 80.64 ± 24.87 80.32 ± 20.65 0.965
Factor VIII:C (%) 38 70–120 152.32 ± 40.70 147.57 ± 46.92 156.89 ± 34.04 0.497
Factor IX (%) 45 70–120 100.20 ± 28.80 102.89 ± 31.62 97.40 ± 25.96 0.529
Factor X (%) 39 70–120 83.78 ± 21.66 83.52 ± 25.23 84.00 ± 18.72 0.728
Factor XI (%) 27 70–120 74.61 ± 24.35 71.03 ± 23.98 77.48 ± 25.09 0.505
Factor XII (%) 37 70–140 50.09 ± 22.30 45.31 ± 18.78 54.86 ± 25.12 0.376
Factor XIII (%) 51 70–140 66.22 ± 17.16 66.30 ± 18.19 66.14 ± 17.16 0.973
Table 4 Transfusion and  substitution of  coagulation fac-
tors (N = 63)
PRBC packed red blood cells, FFP fresh frozen plasma, AT III antithrombin III, AT 
III unit á 500 IE; Factor XIII unit á 1250 IE. Values are displayed as mean ± SD. 
Differences were analyzed using Mann–Whitney U test and were considered 
significant if p ≤ 0.05. For multivariable test, values ≤0.1 were considered for 
further analyses
All NO VT/VTE VT/VTE p
PRBC Units (U) 21.86 ± 26.15 17.15 ± 22.54 27.38 ± 29.27 0.068
PRBC U/day 0.96 ± 1.12 0.88 ± 0.84 1.31 ± 1.88 0.629
Platelets U 5.00 ± 9.17 3.97 ± 7.68 6.21 ± 10.68 0.532
Platelets U/day 0.20 ± 0.45 0.18 ± 0.31 0.30 ± 0.68 0.862
FFP U 4.97 ± 10.36 3.12 ± 7.38 7.14 ± 12.83 0.092
FFP U/day 0.30 ± 0.87 0.24 ± 0.89 0.38 ± 0.85 0.138
AT III U** 1.61 ± 3.12 1.76 ± 3.67 1.43 ± 2.33 0.955
AT III U/day** 0.08 ± 0.17 0.09 ± 0.20 0.07 ± 0.13 0.861
Factor XIII 2.35 ± 3.38 1.71 ± 2.43 3.10 ± 4.16 0.118
Factor XIII U/day 0.12 ± 0.16 0.10 ± 0.14 0.14 ± 0.17 0.290
Table 5 Multivariable analysis
%aPTT denotes the number PTT values over 50 s divided by the total number of 
aPTT measurements times 100, FFP fresh frozen plasma, PRBC packed red blood 
cells; Hosmer–Lemeshow test 0.56; Nagelkerkes R2 0.331
Odds ratio 95 % CI low 95 % CI high p
%aPTT > 50 s 0.974 0.952 0.997 0.024
Time on ECMO 1.047 1.006 1.091 0.026
Fibrinogen 0.995 0.990 1.001 0.090
FFP 1.042 0.958 1.132 0.337
PRBC 0.984 0.950 1.019 0.361
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One of these patients died 24 days after weaning from 
device due to multiseptic organ failure following LTX 
and underwent postmortem examination.
The autopsy did not report VT or VTE possibly due to 
thrombus dissolution under prolonged anticoagulation. 
PE was consequently diagnosed in 5/21 deceased patients 
(24  %). Pulmonary embolism was only systematically 
evaluated for in deceased patients, so no adequate inci-
dence for PE in the whole population can be given from 
this data. Reasons for PE in deceased patients might also 
be associated with circumstances and treatment modali-
ties prior to end of life.
The management of anticoagulation, especially in pro-
longed ECMO support and in patients with sepsis and 
septic shock, is unclear. A recent ELSO survey showed 
that anticoagulation policies vary widely by center [20]. 
Bleeding is common in ECMO and cerebral bleeding, 
occurring at a rate of 4–15  %. In the majority of these 
patients, the outcome is deleterious [21–25]. Bleeding 
risk and transfusion requirements need to be balanced 
against VT/VTE risk, and this might likely end up in less 
anticoagulation. Mostly, aPTT around 50  s is recom-
mended to minimize the risk of bleeding [4, 21, 22, 26]. 
This might provoke an increase in VT and VTE. We tar-
geted a mean aPTT of 50–60  s, and our average aPTT 
was slightly above 50  s. The group of VT/VTE patients 
had a lower mean aPTT, possibly in line with the fact that 
they received more packed red blood cells. We assume 
that we missed our anticoagulation target due to bleed-
ing complications. In fact, VT/VTE patients received 
more RPBC in total even though these differences did not 
reach statistical significance. Bleeding is often difficult 
to assess—a loss of 0.3  mL of blood per minute might 
be difficult to quantify but will lead to a loss of 480 mL 
per day. Additionally, there is no consensus on how to 
assess bleeding severity, especially if bleeding occurs at 
sites that are not easily accessible. Melena can be such an 
example; patients can lose significant amounts of blood, 
but quantification other than with the number of trans-
fused RPBCs is impossible.
Our data are in line with the work of Rastan et al. [13] 
who analyzed autopsy results of patients undergoing 
veno-arterial ECMO support after cardiac surgery. They 
identified cardiac ECMO support > 2 days as an independ-
ent risk factor for systemic thromboembolic events and 
found systemic thromboembolic events in 36/78 patients 
(46.2 %) [13]. Compared to cardiac ECMO support, respir-
atory ECMO runs are often much longer. Cardiac ECMO 
runs were 3.5 ± 3.2 days in the study of Rastan et al. [13] 
versus 22.4 ±  17.4 in our pulmonary patients study. We 
also observed a trend toward longer duration of support in 
VT/VTE patients (p = 0.040). However, VT/VTE was also 
detected in short ECMO runs.
Our study has several limitations, which we would like 
to address. Many limitations are due to the retrospec-
tive nature and the low number of patients included in 
this work. One major limitation is based on the fact that 
we did not have a standardized screening protocol. The 
group of ECMO survivors has not been systematically 
analyzed. This might lead to an underestimation of the 
overall incidence.
Nevertheless, it has to be assumed that VT and VTE 
is an important and underdiagnosed complication of 
respiratory ECMO support and has impact on mid- and 
long-term outcomes. While we met common recommen-
dations for anticoagulation on ECMO, the VT/VTE inci-
dence was still high. Our results tend to underestimate 
the true incidence of VT/VTE in ECMO patients. Hence, 
it might be important to aim at higher aPTT times to 
prevent VT/VTE in a cohort of patients with a high-risk 
profile for VT/VTE.
Conclusions
VT and VTE are common in patients following ECMO 
therapy. Rethinking anticoagulation might be needed as 
novel ECMO circuits show a high degree of biocompat-
ibility and heparinization is to a lesser extent needed in 
the circuit as in the patient to prevent clotting. Current 
aPTT recommendations might be too low to avoid VT 
and VTE. The trend to recommend even lower aPTT tar-
gets might aggravate the problem in the future. Higher 
aPTT recommendations have to be carefully weighed 
against the risk of bleeding, as bleeding, especially intrac-
ranial hemorrhage, has deleterious consequences.
 To achieve optimal outcomes, we recommend VT 
screening following ECMO therapy.
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